These guidelines have been provided by the Endocrinology Team at NBT so pathways might be slightly different at UHBW
Definition
The production of abnormally large volumes of (usually dilute) urine. Clinically defined as >3/L of urine in 24 hours
Often occurs in conjunction with polydipsia and may be either a cause or effect
Distinguish as separate from urinary frequency. This is the excessive need to urinate which is not normal for the patient; but the total volume of urine passed is within normal limits
Important points
Determine the patient’s daily fluid intake (to determine whether this in excess) and their urine output – this can be done at home with a fluid chart
Take a full drug history to consider drugs that can cause polyuria e.g. diuretics, caffeine, alcohol, lithium (causing nephrogenic diabetes insipidus)
Clinical examination should focus on blood pressure, signs of dehydration and weight loss (e.g. diabetes, thyrotoxicosis). Clinical examination rarely reveals specific findings but may point towards the diagnosis based on the diseases most likely to cause polyuria:
Non urgent referral via eRS for the following cases:
An early morning random serum osmolality ≥295mOsmol/Kg or hypernatraemia (Na≥145 mmol/L) with no obvious cause
An early morning random urine osmolality between 200 and 750 mOsm/kg – may benefit from further investigation/clinic review
An urgent referral via eRS is advised if the random early morning urine osmolality is <200 mOsm/kg in a patient who has normal oral intake. These patients are likely to need a formal water deprivation test organising.
Further investigations
Confirm polyuria based on the 24 hour urine volume i.e. >3L in 24 hours
U&Es, calcium group
TFTs – TSH, free T4
Random fasting glucose or HbA1c
Urine MC&S – exclude a UTI
Early morning random paired urine and serum osmolality and urine sodium
References:
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.